title: Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
abstract: We have infused recombinant factor VIIa into patients with hereditary factor VII deficiency with marked reductions in plasma concentrations of factor IX activation peptide (FIXP), factor X activation peptide (FXP), and prothrombin activation fragment F1+2. These investigations show substantial elevations in these markers of coagulation activation and thereby demonstrate that the factor VII-tissue factor pathway is largely responsible for the activation of factor IX as well as factor X in the basal state (ie, the absence of thrombosis or provocative stimuli). We have administered a monoclonal antibody purified factor IX concentrate to individuals with hemophilia B. These studies show an increase in the plasma levels of FIXP that were initially greatly decreased, but no change in FXP or F1+2. We have also infused highly purified factor VIII concentrate into patients with hemophilia A. The data demonstrate no significant changes in the plasma concentrations of FXP and F1+2. The above observations indicate that factor IXa generated by the factor VII-tissue factor pathway is unable to activate factor X under basal conditions. Based upon the above findings, we outline a model of blood coagulation system function under basal conditions, and suggest a process by which the generation of factor Xa and thrombin might be accelerated during normal hemostasis and in the setting of thrombotic disorders.
authors.affiliation: Department of Medicine, Beth Israel Hospital, Boston, MA 02215.
authors.forename: K A
authors.initials: KA
authors.lastname: Bauer
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: F
authors.initials: F
authors.lastname: Tradati
authors.forename: S
authors.initials: S
authors.lastname: Barzegar
authors.forename: B L
authors.initials: BL
authors.lastname: Kass
authors.forename: H
authors.initials: H
authors.lastname: ten Cate
authors.forename: A S
authors.initials: AS
authors.lastname: Kestin
authors.forename: D B
authors.initials: DB
authors.lastname: Brettler
authors.forename: R D
authors.initials: RD
authors.lastname: Rosenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D001777:Blood Coagulation; D015949:Factor IXa / Q000378:metabolism*; D005167:Factor VII / Q000378:metabolism*; D005168:Factor VII Deficiency / Q000097:blood* / Q000628:therapy; D015944:Factor VIIIa / Q000378:metabolism*; D015942:Factor VIIa / Q000627:therapeutic use*; D005170:Factor X / Q000378:metabolism* / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000097:blood* / Q000628:therapy; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values
chemical_list: D000911:Antibodies, Monoclonal; D010446:Peptide Fragments; D011994:Recombinant Proteins; C045879:prothrombin fragment 1.2; D015944:Factor VIIIa; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X; D015942:Factor VIIa; D015949:Factor IXa